A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.
<h4>Background</h4>We previously found that a very low geno2pheno false positive rate (FPR ≤ 2%) defines a viral population associated with low CD4 cell count and the highest amount of X4-quasispecies. In this study, we aimed at evaluating whether FPR ≤ 2% might impact on the viro-immuno...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7e6433be8198451ca3064997384df80b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7e6433be8198451ca3064997384df80b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7e6433be8198451ca3064997384df80b2021-11-25T06:03:15ZA very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.1932-620310.1371/journal.pone.0105853https://doaj.org/article/7e6433be8198451ca3064997384df80b2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25153969/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>We previously found that a very low geno2pheno false positive rate (FPR ≤ 2%) defines a viral population associated with low CD4 cell count and the highest amount of X4-quasispecies. In this study, we aimed at evaluating whether FPR ≤ 2% might impact on the viro-immunological response in HIV-1 infected patients starting a first-line HAART.<h4>Methods</h4>The analysis was performed on 305 HIV-1 B subtype infected drug-naïve patients who started their first-line HAART. Baseline FPR (%) values were stratified according to the following ranges: ≤ 2; 2-5; 5-10; 10-20; 20-60; >60. The impact of genotypically-inferred tropism on the time to achieve immunological reconstitution (a CD4 cell count gain from HAART initiation ≥ 150 cells/mm(3)) and on the time to achieve virological success (the first HIV-RNA measurement <50 copies/mL from HAART initiation) was evaluated by survival analyses.<h4>Results</h4>Overall, at therapy start, 27% of patients had FPR ≤ 10 (6%, FPR ≤ 2; 7%, FPR 2-5; 14%, FPR 5-10). By 12 months of therapy the rate of immunological reconstitution was overall 75.5%, and it was significantly lower for FPR ≤ 2 (54.1%) in comparison to other FPR ranks (78.8%, FPR 2-5; 77.5%, FPR 5-10; 71.7%, FPR 10-20; 81.8%, FPR 20-60; 75.1%, FPR >60; p = 0.008). The overall proportion of patients achieving virological success was 95.5% by 12 months of therapy. Multivariable Cox analyses showed that patients having pre-HAART FPR ≤ 2% had a significant lower relative adjusted hazard [95% C.I.] both to achieve immunological reconstitution (0.37 [0.20-0.71], p = 0.003) and to achieve virological success (0.50 [0.26-0.94], p = 0.031) than those with pre-HAART FPR >60%.<h4>Conclusions</h4>Beyond the genotypically-inferred tropism determination, FPR ≤ 2% predicts both a poor immunological reconstitution and a lower virological response in drug-naïve patients who started their first-line therapy. This parameter could be useful to identify patients potentially with less chance of achieving adequate immunological reconstitution and virological undetectability.Daniele ArmeniaCathia SoulieDomenico Di CarloLavinia FabeniCaterina GoriFederica ForbiciValentina SvicherAda BertoliLoredana SarmatiMassimo GiulianiAlessandra LatiniEvangelo BoumisMauro ZaccarelliRita BellagambaMassimo AndreoniAnne-Geneviève MarcelinVincent CalvezAndrea AntinoriFrancesca Ceccherini-SilbersteinCarlo-Federico PernoMaria Mercedes SantoroPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 8, p e105853 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Daniele Armenia Cathia Soulie Domenico Di Carlo Lavinia Fabeni Caterina Gori Federica Forbici Valentina Svicher Ada Bertoli Loredana Sarmati Massimo Giuliani Alessandra Latini Evangelo Boumis Mauro Zaccarelli Rita Bellagamba Massimo Andreoni Anne-Geneviève Marcelin Vincent Calvez Andrea Antinori Francesca Ceccherini-Silberstein Carlo-Federico Perno Maria Mercedes Santoro A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. |
| description |
<h4>Background</h4>We previously found that a very low geno2pheno false positive rate (FPR ≤ 2%) defines a viral population associated with low CD4 cell count and the highest amount of X4-quasispecies. In this study, we aimed at evaluating whether FPR ≤ 2% might impact on the viro-immunological response in HIV-1 infected patients starting a first-line HAART.<h4>Methods</h4>The analysis was performed on 305 HIV-1 B subtype infected drug-naïve patients who started their first-line HAART. Baseline FPR (%) values were stratified according to the following ranges: ≤ 2; 2-5; 5-10; 10-20; 20-60; >60. The impact of genotypically-inferred tropism on the time to achieve immunological reconstitution (a CD4 cell count gain from HAART initiation ≥ 150 cells/mm(3)) and on the time to achieve virological success (the first HIV-RNA measurement <50 copies/mL from HAART initiation) was evaluated by survival analyses.<h4>Results</h4>Overall, at therapy start, 27% of patients had FPR ≤ 10 (6%, FPR ≤ 2; 7%, FPR 2-5; 14%, FPR 5-10). By 12 months of therapy the rate of immunological reconstitution was overall 75.5%, and it was significantly lower for FPR ≤ 2 (54.1%) in comparison to other FPR ranks (78.8%, FPR 2-5; 77.5%, FPR 5-10; 71.7%, FPR 10-20; 81.8%, FPR 20-60; 75.1%, FPR >60; p = 0.008). The overall proportion of patients achieving virological success was 95.5% by 12 months of therapy. Multivariable Cox analyses showed that patients having pre-HAART FPR ≤ 2% had a significant lower relative adjusted hazard [95% C.I.] both to achieve immunological reconstitution (0.37 [0.20-0.71], p = 0.003) and to achieve virological success (0.50 [0.26-0.94], p = 0.031) than those with pre-HAART FPR >60%.<h4>Conclusions</h4>Beyond the genotypically-inferred tropism determination, FPR ≤ 2% predicts both a poor immunological reconstitution and a lower virological response in drug-naïve patients who started their first-line therapy. This parameter could be useful to identify patients potentially with less chance of achieving adequate immunological reconstitution and virological undetectability. |
| format |
article |
| author |
Daniele Armenia Cathia Soulie Domenico Di Carlo Lavinia Fabeni Caterina Gori Federica Forbici Valentina Svicher Ada Bertoli Loredana Sarmati Massimo Giuliani Alessandra Latini Evangelo Boumis Mauro Zaccarelli Rita Bellagamba Massimo Andreoni Anne-Geneviève Marcelin Vincent Calvez Andrea Antinori Francesca Ceccherini-Silberstein Carlo-Federico Perno Maria Mercedes Santoro |
| author_facet |
Daniele Armenia Cathia Soulie Domenico Di Carlo Lavinia Fabeni Caterina Gori Federica Forbici Valentina Svicher Ada Bertoli Loredana Sarmati Massimo Giuliani Alessandra Latini Evangelo Boumis Mauro Zaccarelli Rita Bellagamba Massimo Andreoni Anne-Geneviève Marcelin Vincent Calvez Andrea Antinori Francesca Ceccherini-Silberstein Carlo-Federico Perno Maria Mercedes Santoro |
| author_sort |
Daniele Armenia |
| title |
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. |
| title_short |
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. |
| title_full |
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. |
| title_fullStr |
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. |
| title_full_unstemmed |
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. |
| title_sort |
very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line haart. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/7e6433be8198451ca3064997384df80b |
| work_keys_str_mv |
AT danielearmenia averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT cathiasoulie averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT domenicodicarlo averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT laviniafabeni averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT caterinagori averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT federicaforbici averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT valentinasvicher averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT adabertoli averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT loredanasarmati averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT massimogiuliani averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT alessandralatini averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT evangeloboumis averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT maurozaccarelli averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT ritabellagamba averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT massimoandreoni averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT annegenevievemarcelin averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT vincentcalvez averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT andreaantinori averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT francescaceccherinisilberstein averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT carlofedericoperno averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT mariamercedessantoro averylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT danielearmenia verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT cathiasoulie verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT domenicodicarlo verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT laviniafabeni verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT caterinagori verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT federicaforbici verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT valentinasvicher verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT adabertoli verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT loredanasarmati verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT massimogiuliani verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT alessandralatini verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT evangeloboumis verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT maurozaccarelli verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT ritabellagamba verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT massimoandreoni verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT annegenevievemarcelin verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT vincentcalvez verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT andreaantinori verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT francescaceccherinisilberstein verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT carlofedericoperno verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart AT mariamercedessantoro verylowgeno2phenofalsepositiverateisassociatedwithpoorviroimmunologicalresponseindrugnaivepatientsstartingafirstlinehaart |
| _version_ |
1718414230963617792 |